Laboratory Tests Used in the Diagnosis and Treatment of COVID-19 Disease

Öz

Diagnostic tests of COVID-19 are an important part of the epidemic and patient management. Diagnostic molecular, serological and biochemical markers also give important information for the treatment and follow-up of the disease. As time passed, the importance of these data laboratory were better understood and it started to be used more widely in clinical practice. It is clear that severe COVID-19 disease is associated with a potent inflammatory response leading to multi-organ failure. Clinical laboratory plays a critical role in the evaluation of inflammatory markers as well as the close monitoring of potential organ failure indicators in intensive care units. With this article, laboratory data that guide the diagnosis and treatment of COVID-19 disease are tried to be considered as a whole.

Anahtar Kelimeler

• COVID-19
• laboratory data
• biomarkers

COVID-19 Hastalığı Tanı ve Tedavisinde Kullanılan Laboratuvar Testleri

Öz

COVID-19 tanı testleri salgının ve hasta yönetiminin önemli bir parçasıdır. Tanı koydurucu moleküler, serolojik ve biyokimyasal markerlar aynı zamanda hastalığın tedavisi ve seyrinin izleminde önemli bilgiler vermektedir. Zaman geçtikçe laboratuvar verilerin incelenmesiyle bu verilerin önemi daha iyi anlaşılmış ve klinik pratikte daha yaygın kullanılmaya başlanmıştır. Şiddetli COVID-19 hastalığı, çoklu organ yetmezliğine yol açan güçlü bir inflamatuar yanıt ile ilişkili olduğu açıktır. Klinik laboratuvar inflamatuar belirteçlerin değerlendirmesi yanında yoğun bakım ünitelerinde potansiyel organ yetmezliği göstergelerinin yakından izlenmesinde kritik rol oynar. Bu makale ile COVID-19 hastalığı tanı ve tedavisinde yol gösterici olan laboratuar verileri bir bütün olarak ele alınmaya çalışılmıştır.

Anahtar Kelimeler

• COVID-19
• laboratuar verileri
• biyobelirteçler

Kaynakça

1. 1. İskit AT, Tanrıöver MD, COVID-19 Pandemi Raporu (20 Mart-20 Kasım 2020); Hacettepe İç Hastalıkları Derneği Yayınları: 6: Ankara, Türkiye, 2021; s 41. http://hdl.handle.net/11655/23314 (28.05.2021’de erişildi)
2. 2. Bohn MK, Lippi G, et al., Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence, Clinical Chemistry and Laboratory Medicine, 2020, 58(7): 1037–1052. https://doi.org/10.1515/cclm-2020-0722
3. 3. Tekol SD, SARS-CoV-2: Virolojisi ve Tanıda Kullanılan Mikrobiyolojik Testler, Southern Clinics of Istanbul Eurasia, 2020, 31(Suppl): 8-12. DOI: 10.14744/scie.2020.13549
4. 4. Sethuraman N, Jeremiah SS, et al., Interpreting Diagnostic Tests for SARS-CoV-2, The Journal of the American Medical Association, 2020, 323(22): 2249-2251. doi:10.1001/jama.2020.8259
5. 5. Pourbagheri-Sigaroodi A, Bashash D, Laboratory findings in COVID-19 diagnosis and prognosis, Clinical Chimica Acta, 2020, 510: 475–482. doi: 10.1016/j.cca.2020.08.019
6. 6. Wang T, Du Z, et al., Comorbidities and multi-organ injuries in the treatment of COVID-19, The Lancet, 2020, 395(10228): e52. doi: 10.1016/S0140-6736(20)30558-4
7. 7. Lippi G, Plebani M, The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks, Clinical Chemistry and Laboratory Medicine, 2020, 58(7): 1063-1069. doi: 10.1515/cclm-2020-0240.
8. 8. Lippi G, Plebani M, Laboratory abnormalities in patients with COVID-2019 infection, Clinical Chemistry and Laboratory Medicine, 2020, 58(7): 1131-1134. doi: 10.1515/cclm-2020-0198.

9. 9.Tan L, Wang Q, et al., Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study, Signal Transduction Targeted Therapy, 2020, 5: 33. doi: 10.1038/s41392-020-0148-4
10. 10. Zhou F, Yu T, et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, The Lancet, 2020, 395(10229): 1054-1062. doi: 10.1016/S0140-6736(20)30566-3.
11. 11. Guan W.-J, Ni Z.-Y, et al., Clinical Characteristics of Coronavirus Disease 2019 in China, The New England Journal of Medicine, 2020, 382(18):1708-1720. doi: 10.1056/NEJMoa2002032.
12. 12. Yang A.-P, Liu J, et al., The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients, International Immunopharmacology, 2020, 84: 106504. doi: 10.1016/j.intimp.2020.106504
13. 13. Ruan Q, Yang K, et al., Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Medicine, 2020, 46(5): 846-848. doi: 10.1007/s00134-020-05991-x.
14. 14. Meisner M, Update on procalcitonin measurements, Annals of Laboratory Medicine, 2014, 34(4): 263-73. doi: 10.3343/alm.2014.34.4.263.
15. 15. Huang C, Wang Y, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The Lancet, 2020, 395(10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5.
16. 16. Mehta P, McAuley DF, et al., COVID-19: consider cytokine storm syndromes and immunosuppression, The Lancet, 2020, 395(10229): 1033-1034. doi: 10.1016/S0140-6736(20)30628-0.
17. 17. Shoenfeld Y, Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning, Autoimmunity Reviews, 2020, 19(6): 102538. doi: 10.1016/j.autrev.2020.102538.
18. 18. Kernan KF, Carcillo JA, Hyperferritinemia and inflammation, International Immunopharmacology, 2017, 29(9): 401-409. doi: 10.1093/intimm/dxx031.
19. 19. Ruscitti P, Berardicurti O, et al., Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm, Frontiers in Immunology, 2020, 11: 1130. doi: 10.3389/fimmu.2020.01130
20. 20. Cooms EA, Haghbayan H, Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis, Reviews in Medical Virology, 2020, 30(6): 1-9. https://doi.org/10.1002/rmv.2141
21. 21. Wu C, Chen X, et al., Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China, The Journal of the American Medical Association Internal Medicine, 2020,180(7): 934-943. doi:10.1001/jamainternmed.2020.0994
22. 22. Tang N, Li D, Et al., Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, Journal of Thrombosis and Haemostasis, 2020, 18(4): 844-847. doi: 10.1111/jth.14768.
23. 23. Zhang Z, Hou Y, et al., Laboratory findings of COVID-19: a systematic review and meta-analysis, Scandinavian Journal of Clinical and Laboratory Investigation, 2020, 80(6): 441-447.
24. 24. Zhang M, Xiao E, Et al., An emerging marker predicting the severity of COVID-19: Neutrophil-Lymphocyte Count Ratio, Research Square, 2020, doi: 10.21203/rs.3.rs-28850/v1 (28.05.2021’de erişildi)
25. 25. Qin C, Zhou L, et al., Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China, Clinical Infectious Diseases, 2020, 71(15): 762-768. doi: 10.1093/cid/ciaa248.
26. 26. Zhang C, Shi L, et al., Liver injury in COVID-19: management and challenges, The Lancet Gastroenterology and Hepatology, 2020, 5(5): 428-430. doi: 10.1016/S2468-1253(20)30057-1.